pI: 7.9669 |
Length (AA): 741 |
MW (Da): 79891 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
506 | 736 | 1v9f (A) | 78 | 313 | 27.00 | 0 | 1 | 0.56 | -0.1 |
157 | 316 | 5cwj (A) | 4 | 161 | 15.00 | 0.21 | 0.29 | 0.392524 | -0.54 |
215 | 343 | 5j0l (A) | 3 | 130 | 15.00 | 0.75 | 0.08 | 0.355689 | -0.6 |
437 | 736 | 2ist (A) | 7 | 313 | 25.00 | 0 | 1 | 0.510358 | 0.93 |
510 | 725 | 2i82 (A) | 12 | 218 | 29.00 | 0 | 0.97 | 0.442998 | 0.54 |
514 | 737 | 1v9k (A) | 95 | 317 | 34.00 | 0 | 1 | 0.444994 | 0.79 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_126865)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G76050 | RNA pseudourine synthase 2 |
Arabidopsis thaliana | AT5G51140 | RNA pseudourine synthase 7 |
Babesia bovis | BBOV_III011610 | RNA pseudouridylate synthase family protein |
Brugia malayi | Bm1_14425 | Hypothetical 50.0 kDa protein K07E8.7 in chromosome IV, putative |
Candida albicans | CaO19.3177 | DRAP deaminase |
Candida albicans | CaO19.10687 | DRAP deaminase |
Caenorhabditis elegans | CELE_K07E8.7 | Protein K07E8.7 |
Cryptosporidium hominis | Chro.20259 | N-terminal part related to RNA:pseudouridine (psi)-synthases C-terminal portion contains the deaminase domain implicated in Ribo |
Cryptosporidium parvum | cgd2_2420 | Yd1036cp-like RluD, S4+type 1 pseudouridine synthase |
Chlamydia trachomatis | CT_658 | pseudouridine synthase |
Dictyostelium discoideum | DDB_G0281097 | pseudouridine synthase family protein |
Dictyostelium discoideum | DDB_G0280463 | hypothetical protein |
Drosophila melanogaster | Dmel_CG6187 | CG6187 gene product from transcript CG6187-RA |
Drosophila melanogaster | Dmel_CG31719 | CG31719 gene product from transcript CG31719-RD |
Escherichia coli | b2594 | 23S rRNA pseudouridine(1911,1915,1917) synthase |
Escherichia coli | b1086 | 23S rRNA pseudouridine(955,2504,2580) synthase |
Echinococcus granulosus | EgrG_001171400 | ribosomal pseudouridine synthase |
Entamoeba histolytica | EHI_037220 | hypothetical protein, conserved |
Entamoeba histolytica | EHI_124370 | RNA pseudouridylate synthase, putative |
Echinococcus multilocularis | EmuJ_001171400 | ribosomal pseudouridine synthase |
Giardia lamblia | GL50803_16328 | DRAP deaminase |
Homo sapiens | ENSG00000166133 | RNA pseudouridylate synthase domain containing 2 |
Leishmania braziliensis | LbrM.34.5050 | hypothetical protein, conserved |
Leishmania infantum | LinJ.35.5430 | hypothetical protein, conserved |
Leishmania major | LmjF.35.5110 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.34.5110 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_08790 | hypothetical protein |
Mycobacterium leprae | ML1200 | possible pseudouridine synthase |
Mus musculus | 271842 | RNA pseudouridylate synthase domain containing 2 |
Mycobacterium tuberculosis | Rv1540 | Conserved hypothetical protein member of yabO/yceC/yfiI family |
Mycobacterium tuberculosis | Rv3300c | Conserved hypothetical protein |
Mycobacterium ulcerans | MUL_1538 | RluA family pseudouridine synthase |
Mycobacterium ulcerans | MUL_2659 | pseudouridine synthase |
Neospora caninum | NCLIV_059120 | RNA pseudouridylate synthase domain-containing protein, putative |
Neospora caninum | NCLIV_009500 | hypothetical protein |
Neospora caninum | NCLIV_020280 | YDL036Cp-like protein, related |
Oryza sativa | 4342081 | Os06g0717400 |
Onchocerca volvulus | OVOC11280 |
|
Plasmodium berghei | PBANKA_0815000 | pseudouridylate synthase, putative |
Plasmodium falciparum | PF3D7_0914000 | pseudouridylate synthase, putative |
Plasmodium knowlesi | PKNH_0711900 | pseudouridylate synthase, putative |
Plasmodium vivax | PVX_099125 | pseudouridylate synthase, putative |
Plasmodium yoelii | PY02484 | RNA pseudouridylate synthase, putative |
Saccharomyces cerevisiae | YDL036C | pseudouridine synthase PUS9 |
Saccharomyces cerevisiae | YOL066C | bifunctional DRAP deaminase/tRNA pseudouridine synthase RIB2 |
Schistosoma japonicum | Sjp_0097370 | expressed protein |
Schistosoma japonicum | Sjp_0203660 | ko:K01718 pseudouridylate synthase [EC4.2.1.70], putative |
Schistosoma mansoni | Smp_106370 | ribosomal pseudouridine synthase |
Schistosoma mansoni | Smp_047860 | ribosomal pseudouridine synthase |
Schmidtea mediterranea | mk4.000536.07 | |
Trypanosoma brucei gambiense | Tbg972.3.2080 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.3.2130 | RNA pseudouridylate synthase, putative |
Trypanosoma congolense | TcIL3000_3_1240 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.507081.70 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_205410 | RNA pseudouridine synthase superfamily protein |
Toxoplasma gondii | TGME49_316680 | RNA pseudouridine synthase superfamily protein |
Treponema pallidum | TP0339 | hypothetical protein |
Theileria parva | TP01_1009 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_451040 | ribosomal pseudouridine synthase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.2130 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.2130 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.2130 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.3.2130 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b1086 | Escherichia coli | non-essential | goodall |
b2594 | Escherichia coli | essential | goodall |
YOL066C | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_316680 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_205410 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_316680 | Toxoplasma gondii | Probably essential | sidik |
TGME49_205410 | Toxoplasma gondii | Probably essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.